Business
HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program
HCW Biologics conducted investigative study to show safe dose levels of its lead drug candidate in non-human primates that were well tolerated at a level significantly higher than the identified efficacious dose level Program has addressed key challenges for first generation T-cell engagers related to manufacturability, preclinical safety profile, and ability to treat a wide spectrum of solid tumors Program is positioned for a potential high value corporate partnership MIRAMAR, Fla., Sept. 09, 2
About this update from Hcw Biologics Inc.
[{"type":"image","alt":"HCW Biologics Inc.","displaySize":"","headline":null,"caption":"HCW Biologics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1280,"height":720,"url":"https://media.zenfs.com/en/globenewswire.com/41c465fea041fccd686f09c17f724fb7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7moUy8t3X1U.W2z3kffb5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/41c465fea041fccd686f09c17f724fb7","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/jCtnB6eE_nzO_SrPPB16lw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/41c465fea041fccd686f09c17f724fb7","width":1200,"height":675}},"lazy":false},{"type":"text","content":"HCW Biologics conducted investigative study to show safe dose levels of its lead drug candidate in non-human primates that were well tolerated at a level significantly higher than the identified efficacious dose level","length":227,"tagName":"p"},{"type":"text","content":"Program has addressed key challenges for first generation T-cell engagers related to manufacturability, preclinical safety profile, and ability to treat a wide spectrum of solid tumors ","length":184,"tagName":"p"},{"type":"text","content":"Program is positioned for a potential high value corporate partnership","length":70,"tagName":"p"},{"type":"text","content":"MIRAMAR, Fla., Sept. 09, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced today that its scientists have successfully developed second-generation, tissue factor-targeting T-cell engagers against solid tumors, particularly for pancreatic cancer and glioblastoma, constructed with its novel proprietary TRBC product discovery and development platform technology.","length":624,"tagName":"p"},{"type":"text","content":"T-cell engagers (“TCEs”) revolutionized the immunotherapeutic approach against cancer since the first indication was approved for Amgen’s BLINCYTO® (blinatumomab) in 2014. Currently, the U.S. Food and Drug Administration (“FDA”) and other regulatory agencies have approved ei...